Drug expenditure · Norwegian citizens taking one of the following drugs: citalopram (depression), omeprazol (antiulcer), cetirizin (allergy), loratadin…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · patients with induction of remission in ulcerative colitis
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).
1 finding from 1 review
Duration of diarrhoea · Adults and children with cholera diarrhoea
1 finding from 1 review
Stool volume · Adults and children with cholera diarrhoea
1 finding from 1 review
Bacteriological failure · Adults and children with cholera diarrhoea
Tetracycline showed no clear difference in bacteriological failure compared with quinolones (low certainty).
1 finding from 1 review
Duration of diarrhoea · Adults and children with cholera diarrhoea
1 finding from 1 review
Stool volume · Adults and children with cholera diarrhoea
1 finding from 1 review
Bacteriological failure · Adults and children with cholera diarrhoea
Doxycycline may leads to higher bacteriological failure compared with quinolones (low certainty).
1 finding from 1 review
Pain: at 72 hours (canakinumab 150 mg) · acute gout
1 finding from 1 review
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
Canakinumab probably leads to higher inflammation: participants with no swelling at 72 hours (canakinumab… compared with triamcinolone acetonide (moderate certainty).
1 finding from 1 review
Functional disability at 3 months ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Health‐related quality of life ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Global assessment of treatment success · acute gout
Canakinumab probably leads to higher participant global assessment of response to treatment: good or… compared with triamcinolone acetonide (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
Canakinumab showed no clear difference in study withdrawals due to AE (all canakinumab doses) compared with triamcinolone acetonide (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · acute gout
Canakinumab probably leads to higher participants with at least 1 AE (all canakinumab doses) compared with triamcinolone acetonide (moderate certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Benzbromarone showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Probenecid showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review